There was also a significantly reduced OS for patients with germline BRCA1 mutant cancers versus those harboring BRCA2 mutant cancers (515 vs 937 days; HR: 0.49, 95% CI 0.29-0.83; p=0.007) (Figure 4). Here, BRCA1 is linked to cancer.